A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt

Table 3 Criteria weights

#	Criteria	Weight (%)
1	Use in reference countries	23.49
2	Equivalence with the reference product (or reference product)	18.79
3	Manufacturing quality	15.53
4	Pharmacovigilance services	12.94
5	Supply reliability	10.78
6	Previous use in local settings	9.80
7	Macro-economic benefit	8.67

Based on SMART swing weighting, each criterion had a relative weight to participate in the final aggregated score. The weights sum up to 100%. If a product had the best performance for a criterion, it would receive the criterion’s total weight

ISSN: 2052-3211